Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomise... by Moskowitz, Craig H, Dr Prof, Nademanee, Auayporn, Prof, Masszi, Tamas, Prof, Agura, Edward, Prof, Holowiecki, Jerzy, Prof, Abidi, Muneer H, Prof, Chen, Andy I, Prof, Stiff, Patrick, Prof, Gianni, Alessandro M, Prof, Carella, Angelo, Prof, Osmanov, Dzhelil, Prof, Bachanova, Veronika, Prof, Sweetenham, John, Prof, Sureda, Anna, Prof, Huebner, Dirk, MD, Sievers, Eric L, MD, Chi, Andy, PhD, Larsen, Emily K, MS, Hunder, Naomi N, MD, Walewski, Jan, Prof

Get full text

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial by Trněný, Marek, Prof, Lamy, Thierry, Prof, Walewski, Jan, Prof, Belada, David, MD, Mayer, Jiri, MD, Radford, John, Prof, Jurczak, Wojciech, MD, Morschhauser, Franck, Prof, Alexeeva, Julia, MD, Rule, Simon, Prof, Afanasyev, Boris, Prof, Kaplanov, Kamil, MD, Thyss, Antoine, Prof, Kuzmin, Alexej, MD, Voloshin, Sergey, MD, Kuliczkowski, Kazimierz, Prof, Giza, Agnieszka, MD, Milpied, Noel, Prof, Stelitano, Caterina, MD, Marks, Reinhard, MD, Trümper, Lorenz, Prof, Biyukov, Tsvetan, MD, Patturajan, Meera, PhD, Bravo, Marie-Laure Casadebaig, MSc, Arcaini, Luca, Prof

Get full text

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial by Coiffier, Bertrand, Prof, Osmanov, Evgenii A, Prof, Hong, Xiaonan, Prof, Scheliga, Adriana, MD, Mayer, Jiri, Prof, Offner, Fritz, Prof, Rule, Simon, MD, Teixeira, Adriana, MD, Walewski, Jan, Prof, de Vos, Sven, MD, Crump, Michael, Prof, Shpilberg, Ofer, Prof, Esseltine, Dixie-Lee, MD, Zhu, Eugene, PhD, Enny, Christopher, BS, Theocharous, Panteli, PhD, van de Velde, Helgi, MD, Elsayed, Yusri A, MD, Zinzani, Pier Luigi, Prof

Get full text

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThe... by Pfreundschuh, Michael, Prof, Kuhnt, Evelyn, MSc, Trümper, Lorenz, Prof, Österborg, Anders, Prof, Trneny, Marek, Prof, Shepherd, Lois, MD, Gill, Devinder S, MD, Walewski, Jan, MD, Pettengell, Ruth, Prof, Jaeger, Ulrich, Prof, Zinzani, Pier-Luigi, MD, Shpilberg, Ofer, Prof, Kvaloy, Stein, Prof, de Nully Brown, Peter, MD, Stahel, Rolf, MD, Milpied, Noel, Prof, López-Guillermo, Armando, MD, Poeschel, Viola, MD, Grass, Sandra, MD, Loeffler, Markus, Prof, Murawski, Niels, MD

Get full text

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a r... by Hermine, Olivier, Prof, Hoster, Eva, PhD, Walewski, Jan, MD, Bosly, André, MD, Stilgenbauer, Stephan, MD, Thieblemont, Catherine, MD, Szymczyk, Michal, MD, Bouabdallah, Reda, MD, Kneba, Michael, Prof, Hallek, Michael, Prof, Salles, Gilles, Prof, Feugier, Pierre, MD, Ribrag, Vincent, MD, Birkmann, Josef, MD, Forstpointner, Roswitha, MD, Haioun, Corinne, MD, Hänel, Mathias, MD, Casasnovas, René Olivier, MD, Finke, Jürgen, MD, Peter, Norma, MD, Bouabdallah, Kamal, MD, Sebban, Catherine, MD, Fischer, Thomas, Prof, Dührsen, Ulrich, Prof, Metzner, Bernd, MD, Maschmeyer, Georg, MD, Kanz, Lothar, Prof, Schmidt, Christian, MD, Delarue, Richard, MD, Brousse, Nicole, MD, Klapper, Wolfram, MD, Macintyre, Elizabeth, Prof, Delfau-Larue, Marie-Hélène, Prof, Pott, Christiane, MD, Hiddemann, Wolfgang, Prof, Unterhalt, Michael, PhD, Dreyling, Martin, Prof

Get full text

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial by Ardeshna, Kirit M, Dr, Qian, Wendi, PhD, Smith, Paul, MSc, Braganca, Nivette, MSc, Lowry, Lisa, FRCPath, Patrick, Pip, PhD, Warden, June, MSc, Stevens, Lindsey, Pocock, Christopher F E, PhD, Miall, Fiona, MD, Cunningham, David, Prof, Davies, John, FRCP, Jack, Andrew, FRCP, Stephens, Richard, MA, Walewski, Jan, MD, Ferhanoglu, Burhan, Prof, Bradstock, Ken, Prof, Linch, David C, Prof

Get full text

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial by Prince, H Miles, Prof, Kim, Youn H, Prof, Horwitz, Steven M, MD, Dummer, Reinhard, Prof, Scarisbrick, Julia, MD, Quaglino, Pietro, Prof, Zinzani, Pier Luigi, Prof, Wolter, Pascal, MD, Sanches, Jose A, PhD, Ortiz-Romero, Pablo L, Prof, Akilov, Oleg E, MD, Geskin, Larisa, MD, Trotman, Judith, MD, Taylor, Kerry, MBBS, Dalle, Stephane, Prof, Weichenthal, Michael, Prof, Walewski, Jan, Prof, Fisher, David, MD, Dréno, Brigitte, Prof, Stadler, Rudolf, Prof, Feldman, Tatyana, MD, Kuzel, Timothy M, Prof, Wang, Yinghui, MS, Palanca-Wessels, Maria Corinna, MD, Zagadailov, Erin, PharmD, Trepicchio, William L, PhD, Zhang, Wenwen, PhD, Lin, Hui-Min, PhD, Liu, Yi, PhD, Huebner, Dirk, MD, Little, Meredith, MPH, Whittaker, Sean, Prof, Duvic, Madeleine, Prof

Get full text

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without ri... by Pfreundschuh, Michael, Prof, Ho, Anthony D, MD, Cavallin-Stahl, Eva, MD, Wolf, Max, Prof, Pettengell, Ruth, Prof, Vasova, Ingrid, MD, Belch, Andrew, MD, Walewski, Jan, MD, Zinzani, Pier-Luigi, MD, Mingrone, Walter, MD, Kvaloy, Stein, MD, Shpilberg, Ofer, Prof, Jaeger, Ulrich, Prof, Hansen, Mads, Prof, Corrado, Claudia, MD, Scheliga, Adriana, MD, Loeffler, Markus, Prof, Kuhnt, Evelyn, Dipl Math

Get full text